" />
Lung cancer antibody:Imp:Pt:Ser/Plas:Nom:IA - CISMeF
Lung cancer antibody:Imp:Pt:Ser/Plas:Nom:IALOINC code
Preferred Label : Lung cancer antibody:Imp:Pt:Ser/Plas:Nom:IA;
LOINC status : ACTIVE;
LOINC display name : Lung cancer Ab IA [Interp];
LOINC long common name : Lung cancer antibody [Interpretation] in Serum or Plasma by Immunoassay;
LOINC short name : Lung cancer antibody SerPl IA-Imp;
LOINC description : Screening for lung cancer using computerized tomography (CT) has been shown to decrease
mortality by 20%. CT is an expensive procedure that also can reveal non-malignant
changes on the chest CT. The EarlyCDT-Lung assay is a cheaper alternative with fairly
good sensitivity and specificity for detecting early, asymptomatic non-small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC). To achieve the desired specificity
of 90%, the autoantibody cutoff values were chosen based on that goal. The overall
sensitivity/specificity of the assay was determined to be 38%/88%. When the sensitivity
and specificity were measured based on the type of tumor, NSCLC was 34%/88% and SCLC
was 50%/88%.[http://cancerpreventionresearch.aacrjournals.org/content/4/7/1126.long#ref-1];
Has component